Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Halberd TBI
- Development stage
- Preclinical
- Lead developer
- Halberd
- Modality
- Antibody-Based Therapeutics
- Administration
- Extracorporeal, Intranasal
01
Overview
Halberd TBI refers to a therapeutic program developed by Halberd Corporation aimed at treating Traumatic Brain Injury (TBI) through the targeted removal of neurotoxic and inflammatory mediators. The core technology utilizes a proprietary extracorporeal platform designed to filter the blood or cerebrospinal fluid, specifically targeting and eliminating excess glutamate—a primary driver of excitotoxicity—and pro-inflammatory cytokines like Interleukin-6 (IL-6). By interrupting the secondary injury cascade that follows the initial physical trauma, the treatment aims to reduce neuronal death and improve functional outcomes. Additionally, Halberd has investigated the use of these targeted ligands in a nasal spray format to provide a non-invasive alternative for rapid intervention in emergency or field settings.
- Other names
- Halberd TBI therapeuticHalberd TBI treatmentHalberd TBI antibody
02
Targets
Glu (Glutamate)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Halberd TBI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Halberd TBI.